Oncology
Guidelines, trial intelligence, mechanisms and education across oncology practice, from tumour-specific updates to systemic anticancer therapy evidence.
Latest Guidelines
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based on individual patient factors…
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
Test for MSI-H/dMMR before treatment: All patients with advanced or recurrent endometrial cancer should undergo microsatellite instability or mismatch repair deficiency testing prior to dostarlimab consideration,…
Lisocabtagene maraleucel for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment (terminated evaluation)
This NICE evaluation was terminated, meaning lisocabtagene maraleucel is not currently recommended for routine NHS use in relapsed or refractory follicular lymphoma—do not commission or initiate…
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma
First-line treatment option: Acalabrutinib combined with bendamustine and rituximab is recommended as a first-line treatment for untreated mantle cell lymphoma, offering an alternative to standard chemotherapy…
Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia
Use acalabrutinib with venetoclax ± obinutuzumab as first-line treatment for untreated CLL – this combination is recommended by NICE and offers improved outcomes compared to standard…
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane (terminated evaluation)
Evaluation terminated – NICE discontinued appraisal of lutetium-177 vipivotide tetraxetan; this agent is not recommended for routine NHS use and should not be prescribed outside approved…
Trial Radar
Chemo Brain Prehab Project
Colorectal cancer is 37% higher in the North West than the national average and is treated by chemotherapy,…
TrialObservational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with…
PHASE3A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have…
TrialAnatomical Landmarks for Chest Wall Perforators Used for Partial Breast Reconstruction
The aim of this 6-month proof-of-concept study is to map out the chest wall perforators in relation to…
Clinical News
‘Quick skin cancer pathway the best birthday gift’
Richard Alun Jones had a melanoma removed on his 61st birthday.
08 Sep 2026Very hot drinks may damage the food pipe and increase cancer risk
The International Agency for Research on Cancer has classified drinking "very hot" beverages (above 65°C) as probably carcinogenic,…
07 Sep 2026‘I have chronic cancer but I’m not going to die’ – BBC presenter Maryam Moshiri
Polycythaemia vera should be considered in patients with unexplained blood count abnormalities; routine GP testing can identify the…
06 Sep 2026BBC News presenter reveals she has blood cancer
High-profile diagnosis raises public awareness of blood cancer, potentially increasing patient consultations and need for GPs to recognise…
Relevant Mechanisms
BRAF/MEK Pathway — Melanoma
BRAF/MEK Pathway — Melanoma is a clinically relevant Drug Science explainer. The MAPK signalling cascade (RAS-RAF-MEK-ERK) transmits extracellular growth signals…
MechanismBTK Inhibition — B-cell Malignancies
BTK Inhibition — B-cell Malignancies is a clinically relevant Drug Science explainer. Bruton's tyrosine kinase (BTK) is a non-receptor cytoplasmic…
MechanismCDK4/6 Inhibition — Breast Cancer
CDK4/6 Inhibition — Breast Cancer is a clinically relevant Drug Science explainer. Cell cycle progression from G1 to S phase…
MechanismEGFR Pathway
EGFR Pathway is a clinically relevant Drug Science explainer. The epidermal growth factor receptor (EGFR/ErbB1/HER1) is a transmembrane receptor tyrosine…
MechanismHER2 Signalling
HER2 Signalling is a clinically relevant Drug Science explainer. Human epidermal growth factor receptor 2 (HER2/ErbB2) is a receptor tyrosine…
CPD, Podcasts & Webinars
No specialty-tagged education live yet
Oncology education appears here when podcasts, webinars and CPD modules are tagged to this hub.
Useful starting points in Oncology
Chemo Brain Prehab Project
Colorectal cancer is 37% higher in the North West than the national average and is treated by chemotherapy,…
TrialObservational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with…
TrialA Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have…
Education that still supports this area
SGLT2 Inhibitors: From Glycaemia to Heart Failure and Chronic Kidney Disease
recorded webinar focused on SGLT2 Inhibitors in diabetes and metabolic medicine. Use the recording with the slide outline…
WebinarJAK Inhibitors: Updated Safety Signals, Patient Selection and Post-ORAL Surveillance
Recorded webinar focused on JAK inhibitors in rheumatology and immune-mediated inflammatory disease. Reviews JAK-STAT signalling, patient selection, ORAL…
WebinarGLP-1 Agonists: Semaglutide, Tirzepatide and the Cardiovascular Revolution
recorded webinar focused on GLP-1 Agonists in diabetes and metabolic medicine. Use the recording with the slide outline…
Follow Oncology safety updates
Get MHRA safety alerts and clinically relevant updates for this specialty in your ClinicaliQ digest.
Follow Oncology
Choose guideline, trial, Drug Science and education updates for this specialty.